Recently a number of endogenous host defence molecules with antimicrobial activity have been identified in mammals, invertebrates and amphibians (for reviews see Ganz, Selsted & Lehrer, 1990; Boman, 1991; Lehrer, Ganz & Selsted, 1991) . Within this group of antimicrobial agents there are several small peptides (2-4K.) that include the defensins (found predominantly in mammalian phagocytes), cecropins, diptericins, attacins, apidaecins, abaecin, royalisin (all from insect sources) and the magainins (amphibian source). A number of semi-synthetic magainins are currently under development as topical antimicrobial agents with potential dermatological, ophthalmic and periodontal applications (Anonymous, 1992) . This article briefly reviews the current status of the magainins, and considers the structure, mode of action and antimicrobial spectrum of these peptides.
Amongst the defensins, the magainins (or magainin analogues) are the most advanced in terms of commercial development (Rennie, 1993) . It is for this reason that this article focuses on the magainins since they have a greater chance of reaching the clinic than do other host defence peptides.
Magainins were identified in the skin secretions of the African clawed frog, Xenopus laevis, by Zasloff and co-workers (Zasloff, 1987; Zasloff, Martin & Chen, 1988) . These host defense peptides are secreted by granular glands in the skin of the frog in response to tissue injury (MacDonald, Berkowitz & Jacob, 1990) . Magainins 1 and 2 (mgn 1 and 2) (also known as PGS-peptides beginning with glycine and ending with serine) are 23 residue peptides with the following sequences (Zasloff el al., 1988; Williams et al., 1990) : mgnl, Gly-IleGly-Lys-Phe-Leu-His-Ser-Ala-Gly-Lys-PheGly -Lys -Ala -Phe -Val -Gly -Glu -lieMet -Lys -Ser; mgn2, Gly -He -Gly -LysPhe -Leu -His -Ser -Ala -Lys -Lys -PheGly -Lys -Ala -Phe -Val -Gly -Glu -HeMet -Asn -Ser. PGLa (peptide beginning with glycine and ending with leucine amide), is another antimicrobial peptide (21 residues) isolated from frog skin (Williams et al., 1990) and has the following sequence: Gly -MetAla -Ser -Lys -Ala -Gly -Ala -He -AlaGly -Lys -He -Ala -Lys -Val -Ala -LeuLys-Ala-Leu-NH 2 . Although PGLa displays Little sequence homology with mgnl or mgn2 these peptides are all positively charged and can form amphiphilic helices about 30 A in length (Williams et al., 1990) . Because these features are common to polypeptides that bind to lipid bilayers it has been suggested that magainins and PGLa act as transmembrane helical channel former that dissipate the membrane potential (Zasloff, 1987) . Subsequent membrane depolarization studies in Escherichia coli using tetraphenyl phosphonium ion (TPP + ) to measure the membrane potential have indeed confirmed that mgn2 and PGLa dissipate the membrane potential (Westerhoff et al., 1989; Jurectic, 1990) . Although mgnl was not specifically examined in these studies (Westerhoff et al., 1989; Jurectic, 1990) its structural similarity to mgn2 implies a similar mode of action. Antimicrobial agents that dissipate the membrane potential invariably have secondary effects on bacterial metabolism leading to stimulation of autolytic enzyme activity, bacterial lysis and cell death (Oliva et al., 1992) . Although it is not known whether exposure of bacteria to magainins and PGLa leads to bacterial lysis, the bactericidal activity of these peptides (Levison et al., 1990; Silva, Tang & Maloy, 1990 ) is consistent with a chain of events initiated by dissipation of the membrane potential and involving bacterial lysis before cell death.
Since mgn2 and PGLa also depolarize mitochondria (Westerhoff et al., 1989) and liposomes (Juretic, 1990) , it has been suggested that the membrane depolarizing peptides secreted by X. laevis would likely attack all cell membranes in their vicinity (Juretic, 1990) . This relatively non-specific activity would only be useful to the host if it can protect itself from the activity of its own products. This is likely to be achieved post-translationally by the Based on Zasloff et al. 1988; Jacob, MacDonald & Maloy, 1990. generation of active peptides through proteolysis of longer peptide precursors that are presumably secreted on to the skin surface before cleavage occurs to produce the biologically active fragment (Zasloff, 1987; Zasloff el al., 1988; Juretic, 1990) . Indeed, cDNA analysis suggests that mgnl and mgn2 are both present in a single precursor peptide of approximately 160 amino acids which contains one copy of mgnl and two copies of mgn2 (Zasloff, 1987; Zasloff et al., 1988; Juretic, 1990) . Both mgnl and mgn2 are flanked in the precursors by sequences that are putative proteolytic cleavage sites (Zasloff, 1987; Zasloff et al., 1988; Juretic, 1990) .
Early magainins and PGLa had relatively poor antibacterial potencies and a limited spectrum of activity (Zasloff et al., 1988; MacDondald & Maloy, 1990) . To improve peptide activity and spectrum, synthetic analogues have been designed involving selected amino acid substitutions and deletions, repeats of small peptides and protection of sites likely to be susceptible to enzymatic attack (MacDonald & Maloy, 1990) . In particular, optimization of anti-staphylococcal and anti-pseudomonal activity has been sought in order to satisfy the requirements for application of these agents as topical antimicrobials. Compared to mgnl and mgn2, the more recently synthesized peptides MSI-91, -94, -95 and -103 are all more active against Staphylococcus aureus and Pseudomonas aeruginosa (Table) . Further studies have led to the identification and selection of peptides 238, 
